Devyser Diagnostics AB publishes quarterly report for the period April to June 2026

“As previously announced, the second quarter was weaker than expected. Sales were negatively impacted by a temporary inventory adjustment by our single largest distributor. Underlying demand remains strong, and our direct sales markets and other distributor markets are continuing to grow. We are still standing by our positive long-term outlook, as the business model is delivering results, our collaboration with Thermo Fisher Scientific is stronger than ever, and our growth drivers are unchanged.”

Jan Wahlström, CEO, Devyser

The quarter from April to June 2026
· Net sales amounted to SEK 60.2 million (67.4), corresponding to a 10.7 percent decrease. Adjusted for exchange rate fluctuations, net sales decreased by 9.7 percent.
· Gross profit totaled SEK 45.8 million (56.8), corresponding to a gross margin of 76.0 percent (84.2).
· Operating profit (EBIT) amounted to SEK 0.5 million (5.5).
· Profit/loss after tax totaled SEK 1.6 million (1.3).
· Earnings per share before and after dilution amounted to SEK 0.10 (0.08).
· Cash flow from operating activities stood at SEK 12.3 million (2.6).

The period from January to June 2026
· Net sales amounted to SEK 122.0 million (122.2), corresponding to a 0.1 percent decrease. Adjusted for exchange rate fluctuations, net sales increased by 4.9 percent.
· Gross profit totaled SEK 96.2 million (102.4), corresponding to a gross margin of 78.9 percent (83.8).
· Operating profit (EBIT) amounted to SEK 3.1 million (-9.3).
· Profit/loss after tax totaled SEK 4.5 million (-19.3).
· Earnings per share before and after dilution amounted to SEK 0.27 (-1.16).
· Cash flow from operating activities stood at SEK 24.4 million (-3.0).

Important events during the quarter
Devyser completed its acquisition of CyberGene AB
On April 1, the acquisition of 100 percent of the shares in CyberGene AB was completed and closing took place. The acquisition strengthens Devyser’s customer offering in the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. At the time of closing, Devyser issued consideration shares to the seller, Level Bio AB (publ).

A strengthened management team - appointment of a new CFO
In May, Devyser announced that it had appointed Niklas Axelsson as its new CFO, effective no later than November 2026. Niklas has over 25 years of experience in the pharmaceutical, life sciences and financial sectors. Sabina Berlin will transition to a new role, with responsibility for Investor Relations and Corporate Compliance, when Niklas takes up his post.

Devyser won a SEK 8.9 million contract in Italy
In June, Devyser won a contract in the Basilicata Region of Italy, with a total value of SEK 8.9 million. The contract covers several of Devyser’s main diagnostic products and is expected to significantly increase annual revenue, while further strengthening the company’s position in Italy, which is one of its most important European markets.

Important events after the end of the quarter
Weaker sales in the second quarter due to a distributor’s inventory buildup
As the period came to a close, Devyser announced that sales for the second quarter were weaker than expected. Sales were negatively impacted by the fact that the company’s single largest distributor built up a large inventory in 2025 and early 2026, which reduced its need to make purchases during the period.
Sales growth in the Group’s direct markets and other distributor markets remains positive.
Due to the distributor’s inventory buildup, sales to this distributor are also expected to be lower for the remainder of 2026. Sales are expected to return to normal from 2027, and the company is confident about future development and growth.
The company believes that, despite weaker sales during the period, the Group’s cash position and cash flow forecast are satisfactory.

Devyser launched One Lambda Devyser Chimerism Plus
In July, Devyser announced an expanded collaboration with Thermo Fisher Scientific through the launch of One Lambda Devyser Chimerism Plus, a next-generation solution for chimerism analysis following stem cell transplants. The launch strengthens Devyser’s product portfolio, and the product will reach the market through Thermo Fisher’s global network.

Presentation
The report will be presented at an audiocast at 09:00 CEST today. Dial-in number to the teleconference and a conference ID will be received by registering on the link below:
https://events.inderes.com/devyser-diagnostics/q2-report-2026/dial-in

The presentation will also be webcast and can be accessed from the following web address:
https://devyser-diagnostics.events.inderes.com/q2-report-2026/register

This report and previous financial reports are available on the company’s webpage https://investors.devyser.com/en/reports-presentations.